Post-marketing Study Assessing the Long-Term Safety of Abatacept

• Status: Completed
• Trial end date: 2017-02-28
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the risk of infections and malignancies among Rheumatoid Arthritis (RA) patients treated with Abatacept compared to other RA treatments.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Abatacept

Criteria

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Patient has at least two claims for RA (714.xx) in the 180 days prior to and including the index date (baseline period)

• Patient is aged 18 years or older on the index date

• Patient was enrolled in the database for at least 180 days before the index date

• Patient is newly prescribed Abatacept or another RA treatment and has at least two claims for the treatment